Correction to: Prevalence of tumour-infiltrating CD103

Quan Zhou, Yuxi Ou, Xiyu Dai, Xinan Chen, Siqi Wu, Wensun Chen, Mengbo Hu, Chen Yang, Limin Zhang, Haowen Jiang

Abstract readPublished Erratum

In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Comparison of QuPath and HALO Platforms for Analysis of the Tumor Microenvironment in Prostate Cancer.Laboratory investigation; a journal of technical methods and pathology · 2025
Article

4 · The record

Corrections and comments

Erratum for
Prevalence of tumour-infiltrating CD1032023

5 · Who and what money

Authors and funding

10 authors.

Quan Zhou *Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.

Yuxi Ou *Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.

Xiyu Dai *Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.

Xinan Chen *Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.

Siqi WuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.

Wensun ChenDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.

Mengbo HuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-7625-2026

Chen YangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China. yangc_huashan@163.com.ORCID http://orcid.org/0000-0001-6011-4067

Limin ZhangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China. zhalim@fudan.edu.cn.ORCID http://orcid.org/0000-0002-8470-1247

Haowen JiangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China. haowj_sh@fudan.edu.cn.ORCID http://orcid.org/0000-0002-5349-1363

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36941407

DOI10.1038/s41416-023-02211-3

PMCPMC10133239

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.